Stock Events

Stock Events

Adverum Biotechnologies 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes in the ophthalmology space, particularly in treatments for macular degeneration, a key area for Adverum.
Regenxbio
RGNX
Mkt Cap637.69M
REGENXBIO Inc. focuses on the development of gene therapy products, directly competing with Adverum's gene therapy approaches for eye diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops gene therapies targeting various diseases, including those in ophthalmology, overlapping with Adverum's focus areas.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, through its acquisition of AveXis, competes in the gene therapy market, including treatments for ophthalmological conditions.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. has investments in gene therapy for various conditions, potentially competing with Adverum's ophthalmology focus.
Abeona Therapeutics
ABEO
Mkt Cap338.53M
Abeona Therapeutics Inc. works on developing gene therapies for rare diseases, including eye diseases, competing in the same space as Adverum.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has shown interest in gene therapy through acquisitions and development programs that could rival Adverum's offerings.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline plc has ventured into gene therapy, including for ophthalmic diseases, positioning it as a competitor.

About

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Show more...
CEO
Dr. Laurent Fischer M.D.
Employees
155
Country
United States
ISIN
US00773U1088
WKN
000A404YL

Listings

MU
DE
AVU.MU

0 Comments

Share your thoughts

FAQ

What is Adverum Biotechnologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Adverum Biotechnologies stocks are traded under the ticker AVU.MU.
How many employees does Adverum Biotechnologies have?▼
As of September 05, 2026, the company has 155 employees.
In which sector is Adverum Biotechnologies located?▼
Adverum Biotechnologies operates in the Health & Wellness sector.
When did Adverum Biotechnologies complete a stock split?▼
The last stock split for Adverum Biotechnologies was on March 21, 2024 with a ratio of 1:10.
Where is Adverum Biotechnologies headquartered?▼
Adverum Biotechnologies is headquartered in Redwood City, United States.